awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q44613028-3FF666FA-1FE6-4405-B5CA-C762C0DA46FB
Q44613028-3FF666FA-1FE6-4405-B5CA-C762C0DA46FB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44613028-3FF666FA-1FE6-4405-B5CA-C762C0DA46FB
Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
P2860
Q44613028-3FF666FA-1FE6-4405-B5CA-C762C0DA46FB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44613028-3FF666FA-1FE6-4405-B5CA-C762C0DA46FB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c3dc520ae499c62c1d6da9aa44aa23bc52e4e5f8
P2860
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group